Neogenin, Defined as a GD3-associated Molecule by Enzyme-mediated Activation of Radical Sources, Confers Malignant Properties via Intracytoplasmic Domain in Melanoma Cells*

To investigate mechanisms for increased malignant properties in malignant melanomas by ganglioside GD3, enzyme-mediated activation of radical sources and subsequent mass spectrometry were performed using an anti-GD3 antibody and mass spectrometry were performed using an anti-GD3 antibody and anti-neogenin antibody from GD3 cells. Overexpression of Ne-ICD in GD3 cells resulted in the increased cell growth and invasion activity, suggesting that Ne-ICD plays a role as a transcriptional factor to drive malignant properties of melanomas after cleavage with γ-secretase. γ-Secretase was found in lipid/rafts in GD3+ cells. Accordingly, immunocyto-staining revealed that GD3, neogenin, and γ-secretase were co-localized at the leading edge of GD3+ cells. These results suggested that GD3 recruits γ-secretase to lipid/rafts, allowing efficient cleavage of neogenin. ChIP-sequencing was performed to identify candidates of target genes of Ne-ICD. Some of them actually showed increased expression after expression of Ne-ICD, probably exerting malignant phenotypes of melanomas under GD3 expression.

It has been long known that malignant transformation of cells brings about changes in the carbohydrate structures in the glycoproteins and glycolipids expressed on the cell surface (1). In particular, there have been a number of reports on the expression of unique glycosphingolipids in neuroectoderm-derived cancer cells (2), osteosarcomas (3, 4), small lung cancer cells (5, 6), and T-cell leukemia cells (7–9). Some of them have been utilized in the clinical field as tumor markers (10) or target molecules of antibody therapy (11).

Because ganglioside GD3 was reported to be neo-antigen in melanomas (12–14), it has attracted the interests of researchers in cancer immunology field, and its expression in normal and cancer tissues has been analyzed (15). The effects of anti-GD3 antibody therapy in melanomas (16) and various aspects of its roles in melanomas have been also reported (17–19). These results suggest that GD3 plays important roles in the enhancement of malignant properties of melanomas (20, 21) by regulating ganglioside-enriched microdomain (GEM)/rafts (22). However, precise mechanisms for GD3 function in cancers have not yet been clarified.

To investigate how gangliosides are involved in the regulation of cell signaling, we have applied enzyme-mediated activation of radical sources (EMARS) method (23) to identify membrane molecules interacting with gangliosides in the vicinity of cell membrane. One of representative molecules associating with GD3 in melanoma cells was neogenin (24). Neogenin belongs to immunoglobulin (Ig) superfamily and has homology to deleted in colorectal cancer (DCC) (25). Although it has been well known as a receptor for axon repulsion in neuroscience research field (26), little is known about roles in cancers (27) despite its expression in wide range of cancer cells (28).

In this study we investigated functions of neogenin and its intracytoplasmic domain (Ne-ICD) in the phenotypes of GD3-positive melanoma cells and its association with GD3 in GEM/rafts. These results might be the first report on the concrete example of effectors to exert malignant properties of melanomas under melanoma-specific ganglioside, GD3.

**

*This work was supported by Grants-in-aid 15H04696, 15K15080, 25670141, and 24390078 from the Ministry of Education, Culture, Sports, and Technology of Japan (MEXT). This work was also supported by a scholarship from Nakamura-Seiken-kai. The authors declare that they have no conflicts of interest with the contents of this article.

1 To whom correspondence should be addressed: Dept. of Life Biomedical Sciences, Chubu University College of Life and Health Sciences, Matsumoto-cho, 1200, Kasugai, Aichi 487-8501, Japan. Tel.: 81-568-9512; Fax: 81-568-9512; E-mail: koichi@isc.chubu.ac.jp.

2 The abbreviations used are: GEM, glycolipid-enriched microdomain; EMARS, enzyme-mediated activation of radical sources; Ne-ICD, neogenin intracytoplasmic domain; DAPT, N-[N-(3,5-difluorophenyl)acetetyl]-l-alanyll-l-phenyl-glycine tert-butyl ester; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

Results

Expression of Neogenin in GD3+ Cells and Control Cells—At first, we checked GD3 expression on GD3+ cells (G5, G11) and
control cells (V4, V9) by flow cytometry. G5 and G11 cells expressed GD3 strongly, whereas GD3 was scarcely detected in V4 and V9 cells (Fig. 1A). Using these cells, we analyzed mRNA and protein expression levels of neogenin by RT-PCR (Fig. 1B) and Western blotting (Fig. 1C), respectively. Neogenin expression was almost equivalent among all GD3+ cells and control cells.

Neogenin Was Involved in Malignant Phenotypes in Melanoma Cells—To clarify whether neogenin expression is involved in malignant phenotypes in melanoma cells, we suppressed neogenin expression by transfection of anti-neogenin siRNA. At 48 h after transfection, knockdown efficiency was examined by Western immunoblotting, showing strong suppression of neogenin expression (Fig. 2A). Using these siRNA-treated cells, invasion and cell proliferation assays were performed. As shown in Fig. 2B, numbers of invaded cells into the bottom side of chambers were dramatically reduced after knockdown of neogenin in all cell lines (G5, G11, V4, V9). The proliferation rates were also decreased in neogenin-silenced cells compared with control siRNA-transfected cells (Fig. 2C). These results suggested its novel function as a promoting molecule of cancer properties.

A High Amount of Neogenin Was Localized in GEM/Rafts in GD3+ Cells in Contrast with GD3− Cells—Next, we analyzed floating pattern of neogenin using fractions prepared from 1% Triton X-100 extracts by sucrose density gradient ultracentrifugation. As shown in Fig. 3A, there were approximately 50 times more neogenin in GEM/raft fractions in GD3+/H11001 cells (G5) than those in control cells (V9). These data suggested that neogenin shifted to GEM/rafts under GD3 expression.

GD3 Associates with Neogenin—Next, we tried to clarify whether GD3 physically associates with neogenin. To address this issue, we performed immunoprecipitation with an anti-neogenin antibody and subsequent immunoblotting with an anti-GM3 monoclonal antibody (mAb) or an anti-β-actin antibody (lower panel). IB, immunoblot. b, the intensities of bands in a were measured by Image J software and plotted. The intensities of bands of neogenin were normalized by β-actin (n = 3).
Neogenin as an Effector of Ganglioside GD3 in Melanoma Cells

7. Neogenin was co-localized with GD3 at caveolin-1-positive leading edge of GD3+ cells (G5), whereas neogenin and caveolin-1 were not necessarily co-localized in GD3− cells (V9) (Fig. 4B). These results suggested that neogenin associates with GD3, and this association is important for GEM/raft localization, i.e. a switching of neogenin localization in the microdomain may occur based on the GD3 expression in melanoma cells. Neogenin was cleaved by γ-secretase in melanoma cells, and its intracytoplasmic domain (named Ne-ICD) was detected more in GD3+ cells than in control cells.

It is known that a part of γ-secretase is localized in GEM/rafts (30, 31) Goldschneider et al. (32) reported that neogenin was a substrate of γ-secretase and the cleaved product (Ne-ICD) functioned as a transcription factor in HEK293T cells. To analyze whether neogenin is cleaved by γ-secretase also in melanoma cells, we treated cells with proteasome inhibitor (MG132) and/or γ-secretase inhibitor (DAPT, N-[N-[(3,5-difluorophenyl)acetyl]-l-alanyl]-l-phenyl-glycine tert-butyl ester). In the absence of MG132, there was no band of the cleaved product (Ne-ICD) in both GD3+ cells (G5) and control cells (V9) (Fig. 5A, first and fifth lanes from the left end). However, in the presence of MG132, Ne-ICD was detected in GD3+ cells (G5) and control cells (V9) (Fig. 5A, second and sixth lanes from the left end). In the presence of DAPT, we could not detect Ne-ICD in any cells regardless of MG132 (Fig. 5A, third and fourth lanes and seventh and eighth lanes from the left end). These results indicated that neogenin was cleaved by γ-secretase. Interestingly, the amounts of Ne-ICD were more in the GD3+ cells (G5) than in control cells (V9) (Fig. 5Ab), although equivalent expression of total-neogenin and presenilin-1 was observed in GD3+ cells (G5) and control cells (V9) (Figs. 1, B and C, 5Aa (first and fifth lanes from the left end), and 6A). This difference in amounts was apparent especially at the low concentration (0.125–0.25 μM) treatment of MG132 (Fig. 5B). To study the effect of GD3 on the production of Ne-ICD, GD3 was directly added to GD3− cells. The amounts of Ne-ICD increased after the addition of GD3 in a dose-dependent manner in two GD3− cells (Fig. 5C). These results suggested that localization changes of neogenin to GEM/rafts by expression or exogenous addition of GD3 increased the efficiency of neogenin cleavage by γ-secretase.

Presenilin-1 Was Localized in the GEM/Rafts of GD3+ Cells—To analyze intracellular localization of presenilin-1 in melanoma cells, fractions prepared from 1% Triton X-100 extracts were analyzed by Western blotting with an anti-presenilin-1 antibody. Both C-terminal fragment and N-terminal fragment of presenilin-1 were definitely detected in the GEM/raft fraction of GD3+ cells compared with GD3− cells (Fig. 6B). These results suggested the possibility that cleavage of neogenin by γ-secretase occurs in the microdomains of GD3+ cells. Therefore, the physical association between GD3 and neogenin might be important for the cleavage of neogenin by γ-secretase.

Presenilin-1, Neogenin, and GD3 Were Co-localized in GD3+ Melanoma Cells—To examine the intracellular localization of neogenin, GD3, and γ-secretase, we performed immunocyto-
chemistry analysis. Neogenin, GD3, and presenilin-1 were co-
stained at the leading edge of GD3

Overexpression of Ne-ICD Enhanced Malignant Properties of Melanoma Cells—To clarify roles of Ne-ICD in melanoma cells, Ne-ICD cDNA was transfected into GD3 + cells (G5) and control cells. Expression levels of Ne-ICD after transfection were shown in Fig. 8A. Ne-ICD was detected even in the absence of MG132. And neogenin was detected for 6 days. Consequently, overexpression of Ne-ICD considerably increased the number of invaded cells and increased cell proliferation as shown in Fig. 8, B and C. Namely, Ne-ICD overexpression enhanced tumor phenotypes, such as invasion and cell proliferation in GD3 + cells (G5) and control cells (V9).

Target Genes of Ne-ICD Were Identified by Chromatin Immunoprecipitation (ChIP)—We tried to identify the target genes of Ne-ICD in melanoma cells by ChIP. We identified 17 genes that might be regulated by Ne-ICD in melanoma cells (Table 1). To examine the effects of Ne-ICD on the gene expression of these molecules, RT-quantitative PCR was performed using RNA from GD3 + and GD3 − cells before and after transfection of a Ne-ICD expression vector. As shown in Fig. 9A, overexpression of Ne-ICD resulted in the up-regulation of the candidate genes such as GPR126, ST6BP5, MMP-16, SPATA31A1, and S6K etc. Therefore, these molecules seemed to be actual effectors for enhancement of the malignant properties induced under GD3 expression in melanomas.

Discussion

Ganglioside GD3 has been considered as a melanoma-associated glycolipid, and its expression and roles in a wide variety of biological processes have been rigorously studied. In particular, roles in the enhancement of malignant properties of various cancers and mechanisms for such functions have been reported by our group and others. Because understanding of molecular mechanisms by which membrane glycolipids modulate signals transduced via various membrane receptors was considered to be essential for the application of these antigens for cancer treatment, we have studied mechanisms by which
cancer-associated glycolipids enhance signaling pathways leading to the malignant phenotypes of cancer cells (33).

Using a GD3-deficient melanoma cell line N1, it was demonstrated that GD3+ cells undergo increased activation signals such as p130Cas, paxillin, Akt (20), and focal adhesion kinase (21). GD3 expression also resulted in the enhanced cell adhesion to various extracellular matrices (17). Involvement of increased phosphorylation of a Src kinase family, Yes, due to GD3, was also demonstrated in melanomas (18) and in gliomas (34).

Although a number of reports on the functions of cancer-associated glycolipids have been published to date, no mechanisms by which gangliosides directly modulate functions of associating molecules in the vicinity of cell membrane have been reported. To challenge this issue, we have tried to identify GD3-associating molecules using EMARS/MS methods (23). Neogenin was one of the identified candidates as GD3- associated molecules in melanoma cells (24). In the present study we have clarified concrete functions of neogenin in melanomas.

Neogenin is expressed in some normal tissues and plays in critical roles in the regulation of diverse developmental processes (35, 36) and embryogenesis (37). In particular, neogenin has been known as a repulsion receptor for axon guidance (38). As for roles of neogenin in cancer cells, there have been increas-

**FIGURE 4. Neogenin was co-localized with GD3 at caveolin-1-positive leading edge of GD3+ melanoma cells.** Immunocytochemical analysis of G5 (A) and V9 (B) cells with an anti-caveolin-1 antibody (green), an anti-neogenin antibody (blue), and an anti-GD3 mAb (R24) (red). Bar, 20 μm or 10 μm as indicated. High-magnified images of dashed square areas in merged image were shown at the bottom of each image. DIC, differential interference contrast.
ing reports on its expression in various cancers (28, 39–44) and on its functions in cancers (28, 44). However, implication of neogenin in cancer phenotypes is now controversial, i.e. neogenin was considered as a suppressor gene as deleted in colorectal cancer (DCC) in breast cancers (42) and gliomas (43), and it was also reported as a cancer-promoting gene in gastric cancers (45), medulloblastomas (40), and esophageal cancers (46).

In this study it was clearly demonstrated that neogenin, particularly its intra-cytoplasmic domain (Ne-ICD), plays as a driver to promote various cancer phenotypes as shown in the MTT (3-(4,5-dimethyl-thiazolyl-2)-2,5-diphenyltetrazolium bromide) assay and invasion assay using overexpressing and/or silenced cells. Furthermore, not only co-localization of neogenin with GD3 in GEM/rafts, but also physical association of neogenin with GD3, could be shown, suggesting a possibility that formation of molecular complex including GD3 and neogenin might be critical for its localization in GEM/rafts and for enhancement of cleavage of Ne-ICD via γ-secretase activation (Fig. 9B).

**FIGURE 5.** Neogenin was cleaved by γ-secretase, and the Ne-ICD levels were higher in GD3+ melanoma cells and increased in GD3− cells after exogenous addition of GD3. A, a, detection of Ne-ICD in GD3+ cells (G5) and control cells (V9) by Western blotting. Cells (2 × 10^6) were incubated with or without a proteasome inhibitor (MG132, 1 μM) and/or a γ-secretase inhibitor (DAPT, 1 μM). After incubation for 4 h, cells were lysed, and proteins (12.5 μg) were analyzed by Western blotting using an anti-neogenin antibody or an anti-β-actin antibody. b, band intensities of Ne-ICD were measured by Image J™ software and plotted. The intensities were normalized by those of β-actin (n = 3). B, a, levels of Ne-ICD after the treatment with various concentrations of MG132. Cells (2 × 10^6) were incubated with various concentrations of a proteasome inhibitor, MG132 (0–2 μM). After incubation for 4 h, cells were lysed and analyzed by Western blotting as shown in A. b, band intensities were also measured and normalized by β-actin. C, a, amounts of Ne-ICD after the addition of GD3. Cells (2 × 10^6) were incubated with different concentration of exogenous GD3 for 48 h and used for analysis of Ne-ICD by Western blotting. b, band intensities were measured and normalized by Ne-ICD of non-treated cells.
There were a number of reports to suggest that sphingolipids play critical roles in Alzheimer disease-associated proteins for lipid rafts (47). In deed, there have been some reports on the regulation of secretases by glycosphingolipids. Exogenous GM1 enhanced secretion of soluble Aβ from primary cultures of rat cortical neurons transiently transfected with human APP695 cDNA (48). Stimulation of proteolytic activity of BACE was demonstrated in the presence of cerebrosides, anionic glycerol-phospholipids and cholesterol (49). Furthermore, inhibition of glycosphingolipid synthesis reduced secretion of amyloid precursor protein (APP) and Aβ (50). As for γ-secretase, Holmes et al. (51) reported that gangliosides increased γ-secretase activity and elevated the Ab42:Ab40 ratio by reconstituting purified human γ-secretase into detergent-free proteoliposomes. All these results suggest that ganglioside profiles largely affect the activity of γ-secretase probably on the cell membrane. In the present study it was clearly demonstrated that increased γ-secretase activity was involved in the generation of Ne-ICD under GD3 expression. Co-localization of GD3, neogenin, and γ-secretase at the cell membrane suggested this ternary molecular association exerts generation of Ne-ICD, leading to increased expression of multiple genes and enhance malignant properties of cells (Fig. 9B) as described in HEK293T previously (32), whereas precise mechanisms for the activation of presenilin as a main subunit of γ-secretase in the ternary molecular association remain to be investigated.

Malignant melanomas have been one of the most refractory diseases despite of a number of clinical trials toward complete cure (52, 53). mAbs reactive with GD3 has been expected to open a new dimension in the melanoma therapy (54) and showed some promising results (16, 55) by modulating the molecular forms (56–58). However, it seems hard to achieve complete remission in many melanoma patients. Based on the results obtained in this study, neogenin might be also a target in melanoma therapy. Under expression of GD3, 30% of neogenin was localized in GEM/rafts, suggesting that it may associate and cooperate with GD3 to exert enhancement of malignant properties. Therefore, in addition to anti-GD3 mAb, combined use of anti-neogenin antibody might be able to disturb the ternary molecular association and suppress the generation of Ne-ICD, leading to the development of novel therapeutics of melanomas with less adverse effects.

As shown in Fig. 9A, many genes showed increased expression after transfection of a cDNA expression vector of Ne-ICD in both GD3+ and GD3− cells, confirming that these genes were driven by Ne-ICD under GD3 expression (Fig. 9B). GPR126 (G protein-coupled receptor 126) is involved in the angiogenesis by regulating proliferation and migration of endo-
STXBP5 is syntaxin-binding protein 5, also named tomosyn. This protein is involved in the formation of SNARE complex, probably regulating secretion of vesicles by forming a complex with syntaxin-1, SNAP-25, and synaptotagmin (60). This function may modulate malignant properties of melanomas. MMP-16 is a member of metallopeptidase family and mediates a proteolytic switch to promote cell-cell adhesion, collagen alignment, and lymphatic invasion in melanoma (61).

SPATA31A1 is spermatogenesis-associated protein-31A and was defined as one of resticular tumor-associated genes (62). Because testicular antigens are frequently linked to tumor-associated antigens, this gene may be involved in the natures of melanomas. S6K, ribosomal protein S6 kinase, is a well known downstream kinase of mTOR that regulates protein activation/translation leading to increased cell migration (63), glutamine metabolism (64), and many other physiological and pathological processes (65).

Consequently, we have identified molecules that might actually exert enhancing effects on various malignant properties of melanomas. Actual roles of these gene products in malignant

**FIGURE 7. Neogenin was co-localized with GD3 and presenilin-1 in melanoma cells.** Cells were fixed by 4% PFA and permeabilized with 0.1% Triton X-100. After blocking with 2.5% BSA, cells were incubated with a mouse anti-GD3 mAb (R24), a goat anti-neogenin antibody, or a rabbit anti-presenilin-1 (NTF) antibody overnight at 4 °C. Immunostaining of GD3+ cells (G5) (A) and control cells (V9) (B). Green, red, and blue indicate presenilin-1, GD3, and neogenin, respectively (lower panels). Immunostaining with normal IgG was also performed for negative control (upper panels). High-magnified fields of dashed square areas in merged image were shown at the bottom. Bar, 20 μm or 10 μm as indicated. DIC, differential interference contrast.
melanomas and precise mechanisms by which Ne-ICD regulates transcription of these genes remain to be investigated.

**Experimental Procedures**

**Antibodies and Reagents**—The following antibodies were used in this study. Anti-GD3 mAb R24 was kindly provided by Dr. L. J. Old at Memorial Sloan-Kettering Cancer Center (New York). mAb R24 has been verified to react specifically with ganglioside GD3 containing NeuAc-NeuAc- and NeuAc-NeuGc-type disialyl structures (29). Other antibodies were purchased from commercial sources, i.e. mouse anti-GM3 mAb M2590 was from Cosmo Bio (Tokyo, Japan). Rabbit anti-caveolin-1, goat anti-neogenin, and rabbit anti-presenilin-1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), mouse anti-β-actin was from Sigma, rabbit anti-FLAG was from Cell Signaling Technology (Beverly, MA), sheep anti-mouse IgG antibody conjugated with HRP was from Amersham Biosciences, goat anti-rabbit IgG antibody conjugated with HRP was from Cell Signaling Technology (Beverly, MA), horse anti-goat IgG conjugated with HRP was from Vector Laboratories (Burlingame, CA), and Alexa 488-conjugated donkey anti-rabbit IgG (H+L) secondary antibody, Alexa 594-conjugated donkey anti-mouse IgG (H+L) secondary antibody, and Alexa647-conjugated donkey anti-goat IgG were from Invitrogen. Protein G-Sepharose and protein A-Sepharose beads were purchased from GE Healthcare. Proteasome inhibitor MG132 was from Sigma. γ-Secretase inhibitor (DAPT) was from Peptide Institute, Inc. (Osaka, Japan).

**Cell Culture**—GD3+ cells and control cells were established as described (20). Namely, SK-MEL-28-derived N1-cell lacking GD3 expression was transfected with cDNA expression plasmid (pMIKneo) with Effectene™ (Qiagen, Valencia, CA) after single cell cloning with a limiting dilution technique. Consequently, after selection in the medium containing G418 (400 μg/ml), all clones were screened on GD3 expression using flow cytometry as described below. GD3-positive transfectant cells such as G5 and G11 and GD3-negative sublines such as V4 and V9 were established as derivatives from a common parent N1 clone. They were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 7.5% fetal calf serum (FCS) at 37 °C in a humidified atmosphere containing 5% CO₂. Stable transfectants were maintained in the presence of 400

---

**FIGURE 8. Ne-ICD enhanced tumor phenotypes in melanoma cells.** Function of Ne-ICD in melanoma cells. A, Ne-ICD expression after transfection of Ne-ICD cDNA. Cells (2 × 10⁵) were transfected with Ne-ICD (L1455A) with Lipofectamine 2000™. After incubation for 48–144 h, cells were lysed and analyzed by Western blotting (IB) with an anti-neogenin antibody. Cancer phenotypes after overexpression of Ne-ICD were analyzed using an invasion assay (B) and MTT assay (C). B, at 48 h after transfection of the Ne-ICD expression vector, 8 × 10⁵ cells were analyzed using invasion assay as described in Fig. 1E. Relative numbers of invaded cells are presented. C, cells (0.5–1 × 10⁶) were analyzed by MTT assay as described in Fig. 1F. Black lines indicate cells with overexpression of Ne-ICD, and gray lines mean vector controls.
Neogenin as an Effector of Ganglioside GD3 in Melanoma Cells

A list of target genes of Ne-ICD identified by ChIP in GD3+ (G5) cells

| Locus      | Closest gene                      | Fragment |
|------------|-----------------------------------|----------|
| 8q21.3     | MMP16 (matrix metalloproteinase 16)| Intron 1 |
| 16p11.2    | MAPK3, ERK1 (mitogen-activated protein kinase 3)| Intron 4 |
| 6q24.1     | GPR126 (G protein-coupled receptor 126)| Intron 23|
| 9p22.1     | NCKX2, SLC24A2 (sodium/potassium/calcium exchanger 2)| Intron 2 |
| 17p12      | COX10 (cytochrome c oxidase assembly homolog 10)| Intron 5 |
| 14q31-q3.2| S6K (ribosomal protein S6 kinase)  | Intron 7 |
| 14q24.3    | RG56 (regulator of G-protein signaling 6)| 14 kb 3’ |
| 14q24.2    | DPF3, CERD4 (zinc and double PHD fingers, family 3)| 16 kb 3’ |
| 9q22.3     | PTCCH1 (patched-1)                | 70 kb 5’ |
| 9q22.32    | RAD26L2, ECCR6L2 (excision repair cross-complementing rodent repair deficiency, complementation group 6-1) | 290 kb 5’ |
| 9p13.1     | ZNF658 (zinc finger protein 658)  | 33 kb 5’ |
| 9q12       | ANKRDO2A2 (ankyrin repeat domain-containing protein-20A2)| 1540 kb 3’ |
| 9q24.11    | Exostosin-1 (exostosin glycosyltransferase 1) | Intron 2 |
| 6q24.3     | ADGB (androglobin)                | 50 kb 3’ |
| 6q24.3     | STXBPS (syntaxin-binding protein 5, tomosyn)| 330 kb 5’ |
| 17p12      | CMT1A (peripheral myelin protein 22, CDRT1, MPM22)| Intron 12 |
| 9p13.1     | SPATA31A1 (spermatogenesis-associated protein-31A)| 137 kb 3’ |

μg/ml G418 (Sigma). Expression of GD3 has been checked every a few months.

Flow Cytometry—Cell surface expression of GD3 was analyzed by flow cytometry (BD Biosciences). Cells were incubated with mAb R24 for 45 min on ice and then stained with FITC-labeled anti-mouse IgG antibody. Control samples were prepared by using non-relevant mAb with the same subclass.

RT-Quantitative PCR—RNAs were extracted using TRIzol™ reagent (Ambion by Life Technologies). Then, cDNA was generated using oligo(dT) primer and Moloney murine leukemia virus reverse transcriptase (Invitrogen). Quantitative PCR was performed using SsoAdvanced™ Universal SYBR Green Supermix™ (Bio-Rad) and CFX Connect™ Real-Time System (Bio-Rad). Primers used in this study were listed in Table 2.

Construction of a cDNA Expression Vector—Human Ne-ICD cDNA was amplified using primers containing restriction sites for PstI and HindIII by KOD FX (TOYOBO, Tokyo, Japan). After gel purification, TA cloning was performed, and the product was ligated into pCR 2.1-TOPO™ vector (Invitrogen). Then, Ne-ICD was ligated into pCMV2B (Stratagene, La Jolla, CA) between PstI and HindIII sites. A mutated Ne-ICD (L1455A) was generated using a KOD-Plus-Mutagenesis™ kit (TOYOBO).

Gene Transfection and Neogenin Knockdown—Cells (2 × 10⁵) were plated in a 60-mm plastic plate (Greiner Bio-one, Frickenhausen, Germany) and incubated for 24 h. The Ne-ICD (L1455A) expression vector (4 μg) or anti-neogenin siRNAs were transfected into 1 × 10⁶ cells using Lipofectamine 2000™ reagent (Invitrogen). The sequence of siRNAs for neogenin was 5’-CAUAUGACUGACUACUCCATT-3’. This siRNA was purchased from Sigma. Effects of overexpression of Ne-ICD or down-regulation of neogenin were assessed at 48–144 h after the transfection by Western immunoblotting. For invasion assay and MTT assay, cells were collected at 48 h after the transfection.

Western Immunoblotting—Cells (2 × 10⁵) were plated in a 60-mm plastic plate (Greiner Bio-one) and incubated for 24 h in DMEM supplemented with 7.5% FCS. After washing 3 times with PBS, cells were lysed by cell lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na₂EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na₃VO₄, 1 μM leupeptin) (Cell Signaling Technology Inc., Danvers, MA) supplemented with protease inhibitor mixture (Calbiochem) and 1 mM PMSF. Insoluble materials were removed by centrifugation at 10,000 × g for 10 min. Cell lysates (5–20 μg) were separated by SDS-PAGE using 6–15% gels. The separated proteins were transferred onto an Immobilon P™ membrane (Millipore, Billerica, MA). Blots were blocked with 5% BSA in PBS containing 0.05% Tween 20 for 1 h at room temperature. The membrane was probed with 1st antibody. After being washed with PBS containing 0.05% Tween 20, the blots were incubated with a goat anti-mouse IgG, a goat anti-rabbit IgG, or a rabbit anti-goat IgG conjugated with HRP for 45 min to 12 h. Conjugates were visualized with an Enhanced Chemiluminescence™ detection system (PerkinElmer Life Sciences).

Immunoprecipitation—Cells were lysed with 500 μl of cell lysis buffer. Lysates were bounded 10 times with Digital Homogenizer™ (AsOne, Osaka, Japan). After removing insoluble materials by centrifugation at 10,000 × g for 10 min, lysates were incubated with an anti-neogenin antibody (2 μg) for 12 h at 4 °C with rotation. Then, protein G-Sepharose or protein A-Sepharose was added and rotated for 2 h at 4 °C. The beads were washed 3 times with immunoprecipitation washing buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 1 mM Na₂VO₄). Finally, the precipitates were analyzed by Western immunoblotting.

Immunocytochemistry—Cells (5 × 10³) were plated on a glass-bottom dish (Iwaki, Tokyo, Japan) and incubated for 24 h in DMEM supplemented with 7.5% FCS. After washing 3 times with PBS, cells were fixed with paraformaldehyde (4% in PBS) for 10 min at room temperature and then incubated with Triton X-100 (0.1% in PBS) for 10 min at room temperature. Nonspecific binding was blocked with BSA (2.5% in PBS) for 12 h at 4 °C. Cells were incubated with an anti-presenilin-1, an anti-caveolin-1, and anti-neogenin antibodies or mAb R24 in PBS containing 0.5% BSA for 12 h at 4 °C. After washing with PBS, cells were incubated with an Alexa Fluor™ 488-conjugated donkey anti-rabbit IgG, an Alexa Fluor™ 594-conju-
Neogenin as an Effector of Ganglioside GD3 in Melanoma Cells

FIGURE 9. Ne-ICD regulates gene expression. A, expression of target genes of Ne-ICD was examined before and after Ne-ICD overexpression. Ne-ICD cDNA was transfected into GD3+ cells (G5) and control cells (V9) using Lipofectamine 2000™. After incubation for 48 h, total RNA was extracted, and RT-PCR was performed using each primer set of the target gene of Ne-ICD as listed in Table 2. B, a schema to summarize results. a, shows cells without GD3 expression. b, presents enhanced malignant properties in melanoma cells under GD3 expression via Ne-ICD generated in GEM/rafts with β-secretase. Under GD3 expression, neogenin shifted to lipid/rafts and co-localized with GD3 and presenilin-1 in melanoma cells. The amounts of Ne-ICD were more in the GD3+ cells than in control cells. Exogenously added GD3 also increased the efficiency of neogenin cleavage by β-secretase. Ne-ICD translocation to nucleus and works as a transcription factor and regulates transcription of multiple genes. Therefore, these molecules seemed to be actual effectors for enhancement of the malignant properties induced under GD3 expression in melanomas.

ACTB, β-actin.

TABLE 2
A list of primers used in this study

| Gene            | Forward                     | Reverse                      |
|-----------------|-----------------------------|------------------------------|
| Neogenin        | CTGGAAGGGGAGAATTGAGA        | TTGTTAGAGCAAGAGAGCT          |
| GAPDH           | ACTTCAACAGCCACGCAACCACC    | CAACTTGAAGAGAGAGAT           |
| GPR126          | CAACCCAAAGGGCCCTCTCAC       | AAGCCCAAGCTGGATTGACT         |
| SPATA3A1A       | TCAAAGAAAAAACAAACG       | ATCTCGCCCTTTCCTGTGA          |
| RGS6            | GCCCTCTTCCTTGCGCGCTGC      | CTGTTAGAGCAAGAGAGCT          |
| MMP16           | AGCTGCCACGCCCACCAAGA       | AACCCCTCCACACGAAAAA          |
| STXB55          | ATCGGAGAGAACGGGCAGAGA       | TTCTGCTTGGTGCTCCACT         |
| S6K             | TGAGAAGCCCTACTGAGACC       | TGTGTCAGAGACTACACT           |
| COX10           | CGCTGAGCTGAGACTGCG         | CAATGCTGACAAAGAGAGGC         |
| DP3             | CTGAGGGGAGGCCGAGGGGAC      | GTCCTGGCTGAGTTGAGCC          |
| MAPK3           | TACCTGAGCTCGCTCGCTCCCC     | TGCTGTCTTTCCTGGAGATGAG       |
| ZNF658          | CCCGTATATCTGCTGGCGCTCG     | ACAAGAGACCAAGACATCCT         |
| RAD26L2         | CTGCCCTGACATGGAGGTG         | AGAAGTCCACACCTCAGAGAT        |
| ANK20A2         | GCTGCTGCTGCTGCTGCTGCA        | GGCTGTGCTGCTGCTGCTGCTG     |
| EXT1            | GAGAGGCGGCTGCTGCTGCTG      | TGCTGCTGCTGCTGCTGCTGCTG     |
| ADGB            | TTAGAGAGCGAGACTACCA         | GCCTGCTGCTGCTGCTGCTGCTG     |
| CMT1            | TTTCAGCTGGGCTGCTGAGAG       | GCAGTGTGATGAGAGAGAGAT        |
gated donkey anti-mouse IgG, or an Alexa Fluor™ 647-conjugated donkey anti-goat IgG for 12 h at 4°C. Then cells were imaged using a confocal microscope (Fluoview FV10™, Olympus, Tokyo, Japan).

Fractionation of GEM/Rafts—Cells (3 × 10⁶) were washed with PBS 3 times and lysed with the lysis buffer. Lysates were Dounce-homogenized 10 times with a Digital Homogenizer™ (AS One, Osaka, Japan). After removing insoluble materials by centrifugation, lysates were mixed with an equal volume of 80% sucrose in TNE buffer (25 mM Tris-HCl, 1 mM EDTA, 150 mM NaCl, 1 mM Na₂VO₄). Then 30% sucrose and 5% sucrose in TNE buffer were overlaid sequentially. The gradient was formed by ultracentrifugation for 16 h at 4°C at 100,000 × g using a MLS50 rotor (Beckman Coulter Inc., Brea, CA). After ultracentrifugation, 0.5 ml each of fraction was collected from the top of the gradient to yield 10 fractions and used for Western immunoblotting.

ChIP—Cells (4 × 10⁶) were plated in a 15-cm dish (Greiner, Bio-one), and FLAG-Ne-ICD (L1455A) cDNA was transfected. Adherent cells were fixed by dimethyl adipimidate-2 HCl (2.5 mg/ml) in PBS for 5 min at room temperature. Formaldehyde (final 1%) was added and incubated for 10 min at room temperature. Glycine was added to the cells to stop fixation. After washing with PBS, fixed cells were scraped and pelleted by centrifugation at 1500 rpm. Cells were resuspended in ice-cold buffer A and pelleted by centrifugation at 3000 rpm. Cells were resuspended in 200 μl of ice-cold buffer B, and DNA was digested by micrococcocal nuclease (0.5 μl/immunoprecipitation) for 20 min at 37°C. EDTA was added to stop the digest, and cells were pelleted by centrifugation at 13,000 rpm. ChIP buffer was added to the pellet and incubated for 10 min at 4°C and sonicated by Sonicator W-375 Cell Disruptor™ (Heat Systems-Ultrasonics, Inc., Plainview, NY).

Cell extracts were incubated overnight at 4°C with anti-FLAG antibody or normal mouse IgG (5 μg) as a negative control and then precipitated by protein G-Sepharose. Beads were washed with low and high salt solution and eluted by ChIP elution buffer (Cell Signaling Technology). Cross-linking of DNA and proteins were reversed by thermomixer (Eppendorf, Tokyo, Japan) (1200 rpm) for 30 min at 65°C. After digesting proteins by proteinase K for 2 h at 65°C, DNA was purified by DNA purification spin column (Cell Signaling Technology) followed by cloning/sequencing.

Cloning and Sequencing of ChIPed-DNA—Taq-polymerase and dNTPs were added into purified DNA and incubated at 60°C for 10 min to add adenine nucleotide. The DNA fragment was ligated to pCR 2.1-TOPO vector (Invitrogen) and transformed into DH5α competent cells (TOYOBO). Then lysates were incubated for 12 h on the X-Gal (5-bromo-4-chloro-3-indolyl- β-D-galactoside) containing LB plate. X-gal-positive colonies were picked up, and plasmids were purified then sequenced by M13 reverse primer (cag gaa aca gct atg ac).

Invasion Assay and MTT Assay—Invasion and MTT assays were performed as described previously (20).

Exogenous Addition of GD3 to GD3+ Cells—Cells (2 × 10⁶) were plated in a 60-mm plastic plate and incubated for 24 h in DMEM supplemented with 7.5% FCS. GD3 (≥98% purity) (Cayman Chemical, Ann Arbor, MI) was solubilized (1 mg/ml) in a mixture of methanol-chloroform (1:1) and dried in a glass tube by N₂ gas stream. Then it was resuspended in DMEM supplemented with insulin, transferrin, selenium (BD Biosciences) by vortexing and sonication with a bath-type sonicator (Branson™, Branson M5800-J, Emerson-Japan, Kanagawa, Japan) for 10 min in the ice-cold water. This GD3 suspension medium (0, 5, 10, 20 nmol/ml) was added after removing old medium and washing twice with DMEM to cells. After incubation for 48 h, cells were used for Western immunoblotting.

Statistics—Mean values were compared using an unpaired Student’s two-tailed t test; significance was set at p < 0.05 (*) and p < 0.01 (**).

Author Contributions—K. K., Y. Ohkawa, and Y. Ohmi performed the gene expression analysis, cell function analysis, immunoblotting, and immunoprecipitation analysis. Keiko Furukawa performed immunocytostaining. M. O. and T. O. performed ChIP-sequencing analysis to identify the targets of Ne-ICD. N. H., K. H., and N. K. performed the EMARS/MS analysis and fractionation of Triton X-100 extracts. Koichi Furukawa designed the experiments and supervised and wrote the manuscript. All authors reviewed the results and approved the final version of the manuscript.

Acknowledgments—We thank T. Mizuno and Y. Nakayasu for technical assistance.

References

1. Hakomori, S. I., and Murakami, W. T. (1968) Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. Proc. Natl. Acad. Sci. U.S.A. 59, 254–261
2. Lloyd, K. O., and Old, L. J. (1989) Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. Cancer Res. 49, 3445–3451
3. Chang, H. R., Cordon-Cardo, C., Houghton, A. N., Cheung, N. K., and Brennan, M. F. (1992) Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 70, 633–638
4. Shibuya, H., Hamamura, K., Hotta, H., Matsumoto, Y., Nishida, Y., Hattori, H., Furukawa, K., and Ueda, M. (2012) Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 103, 1656–1664
5. Cheres, D. A., Rosenberg, J., Mujoo, K., Hirschowitz, L., and Reisfeld, R. A. (1986) Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolyis. Cancer Res. 46, 5112–5118
6. Yoshida, S., Fukumoto, S., Kawaguchi, H., Sato, S., Ueda, R., and Furukawa, K. (2001) Ganglioside Gi(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 61, 4244–4252
7. Siddiqui, B., Buehler, J., DeGregorio, M. W., and Macher, B. A. (1984) Differential expression of ganglioside GD3 by human leukocytes and leukemia cells. Cancer Res. 44, 5262–5265
8. Meritt, W. D., Casper, J. T., Lauer, S. J., and Reaman, G. H. (1987) Expression of GD3 ganglioside in childhood T-cell lymphoblastic malignancies. Cancer Res. 47, 1724–1730
9. Furukawa, K., Akagi, T., Nagata, Y., Yamada, Y., Shimotohno, K., Cheung, N. K., and Shiku, H. (1993) GD2 ganglioside on human T-lymphotropic virus type I-infected T cells: possible activation of β-1,4-N-acetylgalactosaminyltransferase gene by p40tax. Proc. Natl. Acad. Sci. U.S.A. 90, 1972–1976
10. Cheung, N. K., Saarinen, U. M., Neely, J. E., Landmeier, B., Donovan, D., and Coccia, P. F. (1985) Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 45, 2642–2649
Neogenin as an Effector of Ganglioside GD3 in Melanoma Cells

11. Hakomori, S. (1991) New directions in cancer therapy based on aberrant expression of glycosphingolipids: anti-adhesion and ortho-signaling therapy. Cancer Cells 3, 461–470

12. Carubia, J. M., Yu, R. K., Macala, L. J., Kirkwood, J. M., and Varga, I. M. (1984) Gangliosides of normal and neoplastic human melanocytes. Biochem. Biophys. Res. Commun. 120, 500–504

13. Portoukalian, J., Zwingelstein, G., Abdul-Malak, N., and Doré, J. F. (1978) Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem. Biophys. Res. Commun. 85, 916–920

14. Pukel, C. S., Lloyd, K. O., Travassos, L. R., Dippold, W. G., Oettgen, H. F., and Old, L. J. (1982) GD3, a prominent ganglioside of human melanoma: detection and characterisation by mouse monoclonal antibody. J. Exp. Med. 155, 1133–1147

15. Dippold, W. G., Dienes, H. P., Knuth, A., and Meyer zum Büschenfelde, K. H. (1985) Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. Cancer Res. 45, 3699–3705

16. Houghton, A. N., Mintzer, D., Cordon-Cardo, C., Welt, S., Fliegel, B., Houghton, A. N., Mintzer, D., Cordon-Cardo, C., Welt, S., Fliegel, B., and Welt, S. (1995) Development of a monoclonal anti-GD3 antibody for the study of gangliosides in human tumors. Biochem. Biophys. Res. Commun. 215, 172–177

17. Hakomori, S. I. (2000) Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. J. Biol. Chem. 275, 27213–27223

18. Hamamura, K., Tsuji, M., Hotta, H., Ohmi, Y., Yamashita, M., Shibuya, H., Nakashima, H., Yamauchi, Y., Hashimoto, N., Hattori, H., Ueda, M., Furukawa, K., and Furukawa, K. (2010) Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched micromdomains. J. Biol. Chem. 285, 18526–18537

19. Furukawa, K., Kambe, M., Miyata, M., Tajima, O., Ohmi, Y., Yamauchi, Y., Furukawa, K., and Furukawa, K. (2011) Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J. Biol. Chem. 286, 18526–18537

20. Hamamura, K., Furukawa, K., Hayashi, T., Hattori, T., Nakano, J., Nakashima, H., Okuda, T., Mizutani, H., Hattori, H., Ueda, M., Urano, T., Lloyd, K. O., and Furukawa, K. (2005) Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc. Natl. Acad. Sci. U. S. A. 102, 11041–11046

21. Hamamura, K., Tsuji, M., Ohka, Y., Nakashima, H., Miyazaki, S., Urano, Y., Hattori, T., Hayashi, T., and Furukawa, K. (2008) Down-regulation of neogenin accelerated glioma progression through promoter methylation and its overexpression in SHG-44 induced apoptosis. PLoS ONE 3, e8074

22. Xing, W., Li, Q., Cao, R., and Xu, Z. (2014) Neogenin expression is inversely associated with breast cancer grade in ex vivo. World J. Surg Oncol. 12, 352

Identification and characterization of neogenin, a DCC-related gene. Oncogene 14, 1129–1136

29. Furukawa, K., Yamaguchi, H., Oettgen, H.F., Old, L.J., and Lloyd, K. O. (1989) Human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies. Cancer Res. 49, 191–196

30. Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., Wong, P. C., Xu, H., and Thinakaran, G. (2004) Association of γ-secretase with lipid rafts in post-Golgi and endosome membranes. J. Biol. Chem. 279, 44945–44954

31. Urano, Y., Hayashi, I., Isoo, N., Reid, P. C., Shiba, N., Nomura, N., Tomita, T., Iwasu, T., Takamukoto, T., and Kodama, T. (2005) Association of active γ-secretase complex with lipid rafts. J. Lipid Res. 46, 904–912

32. Goldschneider, D., Rama, N., Guix, C., and Mehlen, P. (2008) The neogenin intracellular domain regulates gene transcription via nuclear translocation. Mol. Cell. Biol. 28, 4086–4079

33. Furukawa, K., Hamamura, K., Okawa, Y., Ohmi, Y., and Furukawa, K. (2012) Disialyl gangliosides enhance tumor phenotypes with differential modalities. Glycoconjug. J. 29, 579–584

34. Ohkawa, Y., Momota, H., Kato, A., Hashimoto, N., Tsuda, Y., Kotani, N., Honke, K., Suzumura, A., Furukawa, K., Ohmi, Y., Natsume, A., Wakabayashi, T., and Furukawa, K. (2015) Ganglioside GD3 enhances invasiveness of gliomas by forming a complex with platelet-derived growth factor receptor α and Yes kinase. J. Biol. Chem. 290, 16043–16058

35. Cole, S. J., Bradford, D., and Cooper, H. M. (2007) Neogenin: a multifunctional receptor regulating diverse developmental processes. Int. J. Biochem. Cell Biol. 39, 1569–1575

36. Wilson, N. H., and Key, B. (2007) Neogenin: one receptor, many functions. Int. J. Biochem. Cell Biol. 39, 874–878

37. Gad, J. M., Keeling, S. L., Wilks, A. F., Tan, S. S., and Cooper, H. M. (1997) The expression patterns of guidance receptors, DCC and Neogenin, are spatially and temporally distinct throughout mouse embryogenesis. Dev. Biol. 192, 258–273

38. Braisted, J. E., Catalano, S. M., Stimac, R., Kennedy, T. E., Tessler-Lavigne, M., Shatz, C. J., and O’Leary, D. D. (2000) Netrin-1 promotes axon growth and is required for proper development of the thalamocortical projection. J. Neurosci. 20, 7592–7601

39. Wu, X., Li, Y., Wan, X., Kayira, T. M., Cao, R., Xu, Z., Zhu, X., and Zhao, G. (2012) Down-regulation of neogenin accelerated glioma progression through promoter methylation and its overexpression in SHG-44 induced apoptosis. PLoS ONE 7, e38074

40. Milla, J. A., Arros, A., Espiñoza, N., Remke, M., Kool, M., Taylor, M. D., Pfister, S. M., Wainwright, B. J., and Palma, V. (2014) Neogenin is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression. Int. J. Cancer 134, 21–31

41. Akin, T., Han, X., Nakayama, H., McNeish, B., Zarakowski, D., Mammoto, A., Klagsbrun, M., and Smith, E. (2014) Netrin-1 promotes medulloblastoma cell invasiveness and angiogenesis, and demonstrates elevated expression in tumor tissue and urine of patients with pediatric medulloblastoma. Cancer Res. 74, 3716–3726

42. Zhang, Q., Liang, F., Ke, Y., Huo, Y., Li, M., Li, Y., and Yue, J. (2015) Overexpression of neogenin inhibits cell proliferation and induces apoptosis in human MDA-MB-231 breast carcinoma cells. Oncol. Rep. 34, 258–264

43. Xing, W., Li, Q., Cao, R., and Xu, Z. (2014) Neogenin expression is inversely associated with breast cancer grade in ex vivo. World J. Surg Oncol. 12, 352

44. Lai Wing Sun, K., Correia, J. P., and Kennedy, T. E. (2011) Netrins: versatile extracellular cues with diverse functions. Development 138, 2153–2169

45. Kim, S. J., Wang, Y. G., Lee, H. W., Kang, H. G., La, S. H., Choi, J. I., Irimura, T., Ro, J. Y., Bresalier, R. S., and Chun, K. H. (2014) Up-regulation of neogenin-1 increases cell proliferation and motility in gastric cancer. Oncotarget 5, 3386–3398

46. Hu, Y. C., Lam, K. Y., Law, S., Wong, J., and Srivastava, G. (2001) Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neo-
genin, Id-1, and CDC25B genes in ESCC. Clin. Cancer Res. 7, 2213–2221
47. van Echten-Deckert, G., and Walter, J. (2012) Sphingolipids: critical players in Alzheimer’s disease. Prog. Lipid Res. 51, 378–395
48. Zha, Q., Ruan, Y., Hartmann, T., Beyreuther, K., and Zhang, D. (2004) GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol. Psychiatry 9, 946–952
49. Kalvodova, L., Kahya, N., Schwille, P., Ehehalt, R., Verkade, P., Drechsel, D., and Simons, K. (2005) Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J. Biol. Chem. 280, 36815–36823
50. Tamboli, I. Y., Prager, K., Barth, E., Heneka, M., Sandhoff, K., and Walter, J. (2005) Inhibition of glycosphingolipid biosynthesis reduces secretion of the /H9252-amyloid precursor protein and amyloid /H9252-peptide. J. Biol. Chem. 280, 28110–28117
51. Holmes, O., Paturi, S., Ye, W., Wolfe, M. S., and Selkoe, D. J. (2012) Effects of membrane lipids on the activity and processivity of purified γ-secretase. Biochemistry 51, 3565–3575
52. Wargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S., and Sullivan, R. I. (2015) Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy. Semin Oncol. 42, 601–817
53. Johnson, D. B., and Sosman, J. A. (2015) Therapeutic advances and treatment options in metastatic melanoma. JAMA Oncol. 1, 380–386
54. Dippold, W. G., Knuth, A., and Meyer zum Büschenfelde, K. H. (1984) Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res. 44, 806–810
55. Kirkwood, J. M., Mascari, R. A., Edington, H. D., Rabkin, M. S., Day, R. S., Whiteside, T. L., Vlock, D. R., and Shipe-Spotloe, J. M. (2000) Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 88, 2693–2702
56. Scott, A. M., Lee, F. T., Hopkins, W., Cebon, J. S., Wheatley, J. M., Liu, Z., Smyth, F. E., Murone, C., Sturrock, S., MacGregor, D., Hanai, N., Inoue, K., Yamasaki, M., Brechbiel, M. W., Davis, I. D., et al. (2001) Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J. Clin. Oncol. 19, 3976–3987
57. Forero, A., Shah, J., Carlisle, R., Triozzi, P. L., LoBuglio, A. F., Wang, W. Q., Fujimori, M., and Conry, R. M. (2006) A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother. Radiopharm. 21, 561–568
58. Lo, A. S., Ma, Q., Liu, D. L., and Junghans, R. P. (2010) Anti-GD3 chimeric sFv-CD28/T-cell receptor ε designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 16, 2769–2780
59. Cui, H., Wang, Y., Huang, H., Yu, W., Bai, M., Zhang, L., Bryan, B. A., Wang, Y., Luo, J., Li, D., Ma, Y., and Liu, M. (2014) GPR126 protein regulates developmental and pathological angiogenesis through modulation of VEGFR2 receptor signaling. J. Biol. Chem. 289, 34871–34885
60. Katoh, M., and Katoh, M. (2004) Identification and characterization of human LLGL4 gene and mouse Llgl4 gene in silico. Int. J. Oncol. 24, 737–742
61. Tatti, O., Gucciardo, E., Pekkonen, P., Holopainen, T., Louhiimo, R.,Repo, P., Maliniemi, P., Lohi, J., Rantanen, V., Hautaniemi, S., Alitalo, K., Ranki, A., Ojala, P. M., Keski-Oja, J., and Lehti, K. (2015) MMP16 mediates a proteolytic switch to promote cell-cell adhesion, collagen alignment, and lymphatic invasion in melanoma. Cancer Res. 75, 2083–2094
62. Luk, J. M., Lee, N. P., Sham, C. K., Lam, B. Y., Siu, A. F., Che, C. M., Tam, P. C., Cheung, A. N., Yang, Z. M., Lin, Y. N., Matzuk, M. M., Lee, K. F., and Yeung, W. S. (2006) Acrosome-specific gene AEP1: identification, characterization and roles in spermatogenesis. J. Cell. Physiol. 209, 755–766
63. Raimondi, C., and Falasca, M. (2011) Targeting PDK1 in cancer. Curr. Med. Chem. 18, 2763–2769
64. Csibi, A., Lee, G., Park, S. O., Tong, H., Ilter, D., Elia, I., Fendt, S. M., Roberts, T. M., and Blenis, J. (2014) The mTORC1/S6K1 pathway regulates glutamine metabolism through the elf4b-dependent control of c-Myc translation. Curr. Biol. 24, 16643–16643
65. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., and Blenis, J. (1994) PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 370, 71–75